Intercept Pharmaceuticals Inc is a company known for its strong values and corporate philosophy. The company is committed to delivering innovative treatments and solutions for patients with liver and other metabolic diseases. Intercept Pharmaceuticals Inc places a high emphasis on scientific rigor, integrity, and patient-focused approaches. With an unwavering dedication to quality and excellence, the company strives to provide breakthrough therapies to improve the lives of individuals worldwide. By continuously pushing boundaries and investing in cutting-edge research, Intercept Pharmaceuticals Inc is shaping the future of medical advancements in hepatology and beyond.

Intercept Pharmaceuticals Inc is primarily present in the United States and Europe. As a renowned pharmaceutical company, Intercept has established its presence in major countries and regions within these continents. The company has successfully expanded its operations and is actively engaged in conducting clinical trials, seeking regulatory approvals, and commercializing its innovative therapeutics in these markets. With its headquarters located in New York City, Intercept Pharmaceuticals Inc continues to thrive and enhance its footprint in the healthcare industry across various countries and regions, providing innovative solutions and improving patient outcomes.

Intercept Pharmaceuticals Inc has achieved significant milestones in its history. One of the notable achievements is the FDA approval of its drug Ocaliva® (obeticholic acid) in 2016, for the treatment of primary biliary cholangitis (PBC). This approval marked a major breakthrough in the treatment options for PBC patients. Additionally, Intercept Pharmaceuticals Inc has made progress in clinical trials for its drug candidate, OCA, which is being evaluated for the treatment of nonalcoholic steatohepatitis (NASH). The company has also expanded its global presence, actively collaborating with healthcare professionals and researchers to advance liver disease management. Intercept Pharmaceuticals Inc continues to strive for further innovation and development within the pharmaceutical industry.

Intercept Pharmaceuticals Inc is a biopharmaceutical company headquartered in New York, USA. Founded in 2002, Intercept focuses on the development and commercialization of innovative therapeutics to treat progressive liver diseases. The company's primary focus is on developing treatments for non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and other liver diseases. Intercept made significant advancements with its flagship drug, Ocaliva, which received regulatory approvals for treating PBC and advanced fibrosis due to NASH. With a dedicated team of researchers and clinical experts, Intercept Pharmaceuticals Inc continues to expand its pipeline and strive for breakthrough treatments in the field of liver diseases.

The main competitors of Intercept Pharmaceuticals Inc in the market are AbbVie Inc., Gilead Sciences Inc., and Bristol-Myers Squibb Company.

Intercept Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

The business model of Intercept Pharmaceuticals Inc revolves around developing and commercializing innovative therapeutics to address unmet medical needs in the field of liver and other related diseases. The company focuses on developing novel small molecule drugs to treat chronic liver diseases like nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), and other liver fibrosis-related conditions. Intercept Pharmaceuticals is committed to advancing scientific research and improving patients' lives by introducing effective treatment options. With a strong pipeline of potential therapies, the company aims to establish itself as a leader in the liver disease pharmaceutical market.

Intercept Pharmaceuticals의 P/E 비율은 7.37입니다.

Intercept Pharmaceuticals의 P/S 비율은 1.74입니다.

Intercept Pharmaceuticals에 대한 AlleAktien 품질 점수는 6/10입니다.

예상되는 Intercept Pharmaceuticals 매출은 368.48 백만 USD입니다.

예상되는 Intercept Pharmaceuticals 이익은 87.25 백만 USD입니다.

Intercept Pharmaceuticals Inc. is a global biotechnology company focused on the discovery, development, and commercialization of therapeutics for the treatment of chronic liver diseases and other metabolic disorders. The company was founded in 2002 and is headquartered in New York City. Intercept's business strategy is based on identifying and developing innovative therapy approaches for treating various diseases that represent significant medical needs worldwide. The company's product portfolio focuses on the development of drugs specifically targeting the enzyme that is the main cause of liver diseases and other metabolic disorders. Intercept Pharmaceuticals' flagship product is Ocaliva (Obeticholic Acid), an FXR agonist for the treatment of primary biliary cholangitis (PBC). PBC is a rare chronic inflammatory liver disease in which the immune system attacks and destroys the bile ducts in the liver. Ocaliva is the first medication approved by the FDA for the treatment of PBC after choleretic therapy. In addition to Ocaliva, Intercept Pharmaceuticals is also working on the development of other drugs for the treatment of liver diseases and other metabolic disorders. Another promising product is INT-767, a dual FXR/TGR5 agonist being developed for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Intercept Pharmaceuticals is also pursuing a comprehensive clinical development strategy to find new applications and indications for its products. The company collaborates closely with patient organizations, universities, and companies to support the research of liver diseases and other metabolic disorders. Intercept Pharmaceuticals also has a strong presence in the global market. The company has entered into distribution partnerships with leading pharmaceutical companies worldwide to bring its products to market faster and more reliably. In the United States, Ocaliva is distributed in collaboration with the Japanese pharmaceutical company Sumitomo Dainippon Pharma. In Europe, Intercept Pharmaceuticals works with the French company Genfit. In addition to its product development and distribution strategy, Intercept Pharmaceuticals is also heavily involved in research and development. The company invests significant resources in researching new technologies and therapeutics to expand its product range and identify new applications. Intercept Pharmaceuticals collaborates closely with leading universities and research institutions worldwide to advance its research agenda. Overall, Intercept Pharmaceuticals' business model aims to develop and bring innovative therapies for the treatment of liver diseases and other metabolic disorders to market. The company pursues a comprehensive development strategy and collaborates closely with other companies and institutions to drive innovation. Intercept Pharmaceuticals is on a promising growth trajectory and has the potential to become a leading provider of therapeutics for liver diseases and other metabolic disorders.

Intercept Pharmaceuticals은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Intercept Pharmaceuticals의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Intercept Pharmaceuticals의 ISIN은 US45845P1084입니다.

Intercept Pharmaceuticals의 WKN은 A1J5U0입니다.

Intercept Pharmaceuticals의 티커는 ICPT입니다.

지난 12개월 동안 Intercept Pharmaceuticals은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Intercept Pharmaceuticals은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Intercept Pharmaceuticals의 현재 배당 수익률은 입니다.

Intercept Pharmaceuticals은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Intercept Pharmaceuticals은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Intercept Pharmaceuticals은 '건강' 섹터에 속합니다.

Intercept Pharmaceuticals의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Intercept Pharmaceuticals는 0 USD를 배당금으로 지급했습니다.

Intercept Pharmaceuticals의 배당금은 USD에 지급됩니다.